| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue from contract with customer, license and other revenue | 44,044 | 37,929 | 30,015 | 38,783 |
| Cost of sales-Product | 2,113 | 1,051 | - | - |
| Research and development | 30,544 | 32,788 | 34,618 | 36,134 |
| Cost of sales | - | - | 1,301 | 1,300 |
| Selling, general and administrative | 26,607 | 28,477 | 27,352 | 27,632 |
| Total operating expenses | 59,264 | 62,316 | 63,271 | 65,066 |
| Loss from operations | -15,220 | -24,387 | -33,256 | -26,283 |
| Interest income | 553 | 613 | 1,000 | 1,832 |
| Interest expense | 11,008 | 11,228 | 10,994 | 11,385 |
| Gain on extinguishment of debt | 0 | 0 | - | - |
| Other (expense) income, net | -7,418 | -2,210 | 19,824 | 3,792 |
| Total other (expense) income, net | -17,873 | -12,825 | 9,830 | -5,761 |
| Loss before income taxes | -33,093 | -37,212 | -23,426 | -32,044 |
| Income tax provision | 34 | 40 | 36 | 28 |
| Net loss | -33,127 | -37,252 | -23,462 | -32,072 |
| Basic net income (loss) per common share ( a / b) | -3.82 | -4.32 | -2.77 | -0.26 |
| Earnings per share, diluted, total | -3.82 | -4.32 | -2.77 | -0.26 |
| Weighted average number of shares outstanding, basic | 8,669 | 8,620 | 8,470 | 125,010 |
| Weighted-average number of common shares outstanding used to compute diluted net loss per share | 8,669 | 8,620 | 8,470 | 125,010 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)